Skip to product information
1 of 1

东盟制药

Sorafenib Soranni SORAFENIB TOSYLATE 200 MG 56 tablets Approval No. 09 L 0700/16 Valid until 27-6-2026

Sorafenib Soranni SORAFENIB TOSYLATE 200 MG 56 tablets Approval No. 09 L 0700/16 Valid until 27-6-2026

Regular price ¥525.00 CNY
Regular price ¥1,000.00 CNY Sale price ¥525.00 CNY
Sale Sold out
Shipping calculated at checkout.

The following is the general instructions for Sorafenib Tosylate (trade name: Nexavar). The specific content may vary depending on the manufacturer, so please refer to the actual product instructions.


Drug Name <br>Generic Name: Sorafenib Tosylate Trade Name: Soranni
English name: Sorafenib Tosylate

Ingredients <br>Main ingredient: Sorafenib tosylate.

Indications

  1. Unresectable hepatocellular carcinoma (HCC).
  2. Advanced renal cell carcinoma (RCC).
  3. Thyroid cancer (certain types).

Dosage

  1. Recommended dose : The recommended dose of sorafenib is 400 mg per day (2 tablets of 200 mg), taken orally twice a day in the morning and evening.
  2. How to take : It can be taken with meals or on an empty stomach, but high-fat foods should be avoided to prevent absorption.
  3. Adjust the dose : If serious adverse reactions occur, the dose may be adjusted as appropriate.

Contraindications

  • It is contraindicated for those who are allergic to the active ingredients or any excipients of this product.

Precautions

  1. Cardiovascular Risks : May increase the risk of hypertension and adverse cardiac events; blood pressure and cardiac function should be monitored.
  2. Bleeding risk : Use with caution in patients with bleeding tendencies.
  3. Effects on liver function : People with abnormal liver function should use this drug with caution and monitor liver function regularly.
  4. Pregnant and lactating women : Pregnant women are prohibited from using this drug. Lactating women should stop breastfeeding during the medication period.

Adverse Reactions

  1. Common: diarrhoea, skin reactions (e.g. hand-foot syndrome), hypertension, loss of appetite.
  2. Severe: Myocardial infarction, hemorrhagic events, liver damage.

Drug interactions

  1. Co-administration with CYP3A4 inducers (such as rifampicin) may reduce the efficacy of this product.
  2. Concomitant use with anticoagulants may increase the risk of bleeding.

Storage <br>Keep in a cool and dry place, avoid direct sunlight, and store as required by the instructions.

Manufacturer <br>Laos ASEAN Pharmaceuticals.

Packing Specifications
200 mg/56 tablets.

Expiration date <br>See packaging instructions for details.


Note : The above content is for reference only. Please strictly follow the doctor's advice and drug instructions for specific medication.

View full details